- Price
- $151.99
- Day
- +7.96%
- Mkt Cap
- $2.18B
- 52W Range
- $36.93 – $161.38
- Volume
- 262.7K
- Beta
- -0.17
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Palvella Therapeutics, Inc. (PVLA) Q2 2026 Earnings Call Transcript
Read full article
First module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations submitted to FDA, with completion of the NDA submission on track for the second half of 2026 Preparing for a planned standalone U.S. commercial launch of QTORIN™ rapamycin for microcystic lymphatic malformations in the first half of 2027, if approved Initiation of Phase 3 trial of QTORIN™ rapamycin for the treatment of cutaneous venous malformations planned for the fourth quarter of 2026 Initiation of Phase 2 trial of QTORIN™ pitavastatin for the treatment of disseminated superficial actinic porokeratosis planned for the second half of 2026 Topline results from the Phase 2 LOTU trial of QTORIN™ rapamycin for clinically significant angiokeratomas expected in the second half of 2027 Cash, cash equivalents and short-term investments of $250.6 million as of June 30, 2026 Company to host conference call at 8:30 a.m. ET today WAYNE, Pa.
Read full article
Palvella Therapeutics NASDAQ: PVLA said it remains on track to complete its new drug application submission for QTORIN rapamycin in microcystic lymphatic malformations, or mLM, during the second half of 2026, with potential FDA approval targeted for the first half of 2027.
Read full article
Arete Wealth Advisors LLC purchased a new position in Palvella Therapeutics, Inc. (NASDAQ: PVLA) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 17,470 shares of the company's stock, valued at approximately $2,178,000. Arete Wealth Advisors LLC owned 0.12%
Read full article
Hybrid public meeting on August 5th will explore approaches to selecting and prioritizing promising FDA-approved drugs for repurposing, with the potential to accelerate patient access to effective therapies for significant unmet medical needs
Read full article
WAYNE, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc . (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, announced today that it will report its second quarter 2026 financial results before market open on Tuesday, August 4, 2026. Palvella management will host a conference call for investors at 8:30 a.m. ET on that same day to discuss the results and provide a corporate update.
Read full article
Fifth Third Bancorp bought a new stake in Palvella Therapeutics, Inc. (NASDAQ: PVLA) in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 19,947 shares of the company's stock, valued at approximately $2,486,000. Fifth Third Bancorp owned approximately 0.14%
Read full article